Targeting Urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT

Journal of the National Cancer Institute

Volumn 94, Issue 8, 2002, Pages 597-606

  Vallera, Daniel A ^a   Li, Chunbin ^a   Jin, Ni ^a   Panoskaltsis Mortari, Angela ^b   Hall, Walter A ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DIPHTHERIA TOXIN; HYBRID PROTEIN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; RECOMBINANT PROTEIN; UROKINASE; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ANALYSIS; GLIOBLASTOMA; HEART; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; LIVER LEVEL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPLEEN; STATISTICAL ANALYSIS; STUDENT T TEST; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; UMBILICAL VEIN; UREA NITROGEN BLOOD LEVEL;

EID: 0037123350     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.8.597     Document Type: Article

References (44)

1. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991
2. Neoplasm of the central nervous system
3. Insights about brain tumors gained through immunohistochemistry and in situ hybridization of nuclear and phenotypic markers
4. Immunotoxins in cancer therapy
5. A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: Effects of antibody immunological properties and tumor antigen expression levels
6. Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies
7. Immunotoxins for brain tumor therapy
8. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor
9. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas
10. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice
11. Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor
12. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer
13. Immunohistochemical localization or urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas
14. Components of the plasminogen activation system in uveal melanoma-a clinico-pathological study
15. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer
16. Prevention of metastasis by inhibition of the urokinase receptor
17. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: Implications for capillary-like tube formation in a fibrin matrix
18. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo
19. uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways?
20. The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: Internalization is toxin mediated
21. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases
22. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell
23. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor
24. A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells
25. Reactivity of murine cytokine fusion toxin, diphtheria toxin-murine interleukin-3 (DT390-mIL-3), with bone marrow progenitor cells
26. Up-regulation of interleukin 4/B-cell stimulatory factor 1 receptor expression
27. Molecular modification of a recombinant anti-CD3epsilon-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model
28. Renal dysfunction accounts for the dose limiting toxicity of DT390anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin
29. Retroviral immunotoxin gene-therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene
30. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin
31. Expression and significance of urokinase type plasminogen activator gene in human brain gliomas
32. Binding of human urokinase-type plasminogen activator to its receptor: Residues involved in species specificity and binding
33. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
34. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice
35. Differential binding of urokinase and peptide antagonists to the urokinase receptor: Evidence from characterization of the receptor in four primate species
36. Use of immunotoxin to inhibit proliferating human corneal endothelium
37. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling
38. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma
39. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma
40. Anti-T-cell reagents for human bone marrow transplantation: Ricin linked to three monoclonal antibodies
41. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro
42. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor
43. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors
44. Intraventricular immunotoxin therapy for leptomeningeal neoplasia